Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Sep 30;10(5):00494-2024.
doi: 10.1183/23120541.00494-2024. eCollection 2024 Sep.

Anti-inflammatory reliever therapy (AIR) for asthma

Mark L Levy  1 , Michael G Crooks  2   3
Affiliations
Editorial

Anti-inflammatory reliever therapy (AIR) for asthma

Mark L Levy et al. ERJ Open Res. .

Abstract

SABA overuse is prevalent and dangerous in asthma. Use of anti-inflammatory relievers (ICS/formoterol) in asthma mitigates against risk associated with SABA overuse and poor ICS adherence, and is the preferred approach for asthma management. https://bit.ly/4aHOLn8.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: M.L. Levy has received payments from publishers Taylor Francis and from Class Publishing; consulting fees from Smart Respiratory, Respiri, Imperial College, AstraZeneca, Novartis and TEVA; speaker/writing fees from Chiesi, AstraZeneca and TEVA; honoraria for manuscript writing and educational events from Consorzio Futuro in Ricerca; fees for expert testimony from HM Coroner, Waltham Forrest, London; support to attend meetings from TEVA; and has roles (unpaid) in Global Initiative on Asthma, NHS England and the UK All Party Parliamentary Advisory Group (Asthma, COPD, Inhalers). Conflict of interest: M.G. Crooks has received grants from the National Institute for Health and Care Research, Asthma & Lung UK, AstraZeneca, Chiesi and Phillips; and consultancy and/or honoraria and/or nonfinancial support from AstraZeneca, Chiesi, Gilead and Synairgen.

References

    1. Global Initiative for Asthma . The Global Strategy for Asthma Management and Prevention 2024. Available from: https://ginasthma.org/
    1. Wang H-C, Djajalaksana S, Sharma L, et al. . Evaluation of short-acting beta-2-agonist prescriptions and associated clinical outcomes: findings from the SABA use IN Asthma (SABINA) study in Asia. World Allergy Organ J 2023; 16: 100823. doi:10.1016/j.waojou.2023.100823 - DOI - PMC - PubMed
    1. Janson C, Menzies-Gow A, Nan C, et al. . SABINA: an overview of short-acting β2-agonist use in asthma in European countries. Adv Ther 2020; 37: 1124–1135. doi:10.1007/s12325-020-01233-0 - DOI - PMC - PubMed
    1. Noorduyn SG, Qian C, Johnston KM, et al. . SABA use as an indicator for asthma exacerbation risk: an observational cohort study (SABINA Canada). ERJ Open Res 2022; 8: 00140-2022. doi:10.1183/23120541.00140-2022 - DOI - PMC - PubMed
    1. Montero-Arias F, Garcia JCH, Gallego MP, et al. . Over-prescription of short-acting β2-agonists is associated with poor asthma outcomes: results from the Latin American cohort of the SABINA III study. J Asthma 2023; 60: 574–587. doi:10.1080/02770903.2022.2082305 - DOI - PubMed

Publication types

LinkOut - more resources